Scientists Engineer Probiotic Bacteria to Hunt Tumors and Deliver Cancer Drugs

Cancer treatment may be on the verge of a significant advancement, thanks to a new strategy developed by scientists at Shandong University in China. Researchers have successfully engineered Escherichia coli Nissle 1917 (EcN), a probiotic bacteria, to act as tumor-seeking drug factories. This innovative approach involves modifying the bacteria to produce and deliver an existing cancer drug directly to tumor sites, potentially increasing treatment effectiveness and reducing side effects.

The Promise of Bacteria-Assisted Cancer Therapy

The complexity of cancer treatment often stems from the difficulty of targeting cancerous cells while sparing healthy tissue. Traditional chemotherapy, while effective, can cause significant systemic side effects. Scientists are increasingly exploring the potential of using the body’s own microbiome – the trillions of bacteria, viruses, and fungi that live in and on us – to fight disease.

This research, published on March 17th, 2026, in the open-access journal PLOS Biology, demonstrates that EcN can be genetically engineered to produce Romidepsin (FK228), an FDA-approved drug used in the treatment of certain cancers. The engineered bacteria were then tested in a mouse model of breast cancer.

How Engineered Bacteria Target Tumors

The experiments revealed that the modified EcN bacteria were able to accumulate within tumors and release Romidepsin directly at the site of the cancer. This targeted delivery system allows for a higher concentration of the drug to reach the tumor while minimizing exposure to healthy tissues.

According to the study authors, “Escherichia coli Nissle 1917’s tumor colonization synergizes with Romidepsin’s anticancer activity to form a dual-action cancer therapy.” They believe this approach holds “great promise for cancer treatment” by leveraging engineered EcN to create a bacteria-assisted, tumor-targeted therapy.

Future Directions and Considerations

While these findings are promising, it’s important to note that this research is still in its early stages. The therapy has only been tested in mice, and further studies are needed to determine its safety and efficacy in humans. Researchers will need to address potential side effects and develop strategies for safely removing the bacteria after treatment.

As stated in a ScienceDaily report, more research is needed before this approach can be tested in people. However, this innovative use of engineered bacteria represents a significant step forward in the development of more precise and effective cancer treatments.